Payment overview · 2025
General Payments
$1,121.31
64 reported records · 16 companies
Healthcare provider profile · identity verified
Ram Chandra, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · ODESSA, MO · NPI 1750349874
Verified facts
What the public records show
CMS Open Payments records show Ram Chandra, D.O. received $1,121.31 in general payments during 2025 across 64 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 18.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 342 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 342 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Gemtesa by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $209.46 | 18.7% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $154.01 | 13.7% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $111.02 | 9.9% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $107.67 | 9.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $86.04 | 7.7% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $81.43 | 7.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.41 | 6.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $67.32 | 6.0% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $55.67 | 5.0% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $50.92 | 4.5% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $30.55 | 2.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.25 | 2.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.52 | 1.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.39 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.34 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.31 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,121.31 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $210.93 | 13 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $154.01 | 13 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $107.67 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $86.04 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $81.43 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $68.41 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $67.35 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $67.32 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $67.32 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $55.67 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $50.92 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $42.89 | 3 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $34.37 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $30.55 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $30.25 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 169 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
169 | 33 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
342 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
169 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 20 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
51 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
342 | 33 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 943 | 154 |
| Levothyroxine Sodium | Levothyroxine Sodium | 839 | 122 |
| Pantoprazole Sodium | Pantoprazole Sodium | 509 | 88 |
| Omeprazole | Omeprazole | 493 | 81 |
| Gabapentin | Gabapentin | 482 | 81 |
| Potassium Chloride | Potassium Chloride | 467 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 437 | 81 |
| Lisinopril | Lisinopril | 425 | 76 |
| Metformin Hcl | Metformin Hcl | 405 | 67 |
| Furosemide | Furosemide | 380 | 70 |
| Carvedilol | Carvedilol | 348 | 61 |
| Eliquis | Apixaban | 342 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 311 | 106 |
| Tramadol Hcl | Tramadol Hcl | 307 | 83 |
| Losartan Potassium | Losartan Potassium | 305 | 49 |
| Trazodone Hcl | Trazodone Hcl | 303 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 297 | 59 |
| Lorazepam | Lorazepam | 269 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 262 | 34 |
| Famotidine | Famotidine | 262 | 36 |
| Alprazolam | Alprazolam | 261 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 252 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 245 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 235 | 63 |
| Donepezil Hcl | Donepezil Hcl | 235 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 234 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 232 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 230 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 219 | 34 |
| Montelukast Sodium | Montelukast Sodium | 218 | 39 |
| Sertraline Hcl | Sertraline Hcl | 218 | 33 |
| Warfarin Sodium | Warfarin Sodium | 212 | 18 |
| Meloxicam | Meloxicam | 204 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 200 | 37 |
| Simvastatin | Simvastatin | 199 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 193 | 52 |
| Glimepiride | Glimepiride | 177 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 176 | 39 |
| Allopurinol | Allopurinol | 170 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 170 | 42 |
| Jardiance | Empagliflozin | 169 | 33 |
| Aripiprazole | Aripiprazole | 152 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 151 | 24 |
| Azithromycin | Azithromycin | 133 | 92 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 130 | 24 |
| Xarelto | Rivaroxaban | 129 | 14 |
| Mirtazapine | Mirtazapine | 128 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 127 | 38 |
| Clonazepam | Clonazepam | 120 | 19 |
| Prednisone | Prednisone | 120 | 29 |
| Pregabalin | Pregabalin | 119 | 18 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 116 | suppressed |
| Memantine Hcl | Memantine Hcl | 116 | 15 |
| Topiramate | Topiramate | 116 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 111 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 108 | 27 |
| Ozempic | Semaglutide | 108 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 100 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 100 | 13 |
| Spironolactone | Spironolactone | 99 | 19 |
| Alendronate Sodium | Alendronate Sodium | 97 | 14 |
| Buspirone Hcl | Buspirone Hcl | 96 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 95 | 19 |
| Finasteride | Finasteride | 95 | 14 |
| Olanzapine | Olanzapine | 93 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 92 | 13 |
| Levetiracetam | Levetiracetam | 92 | 16 |
| Temazepam | Temazepam | 92 | 13 |
| Januvia | Sitagliptin Phosphate | 90 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 87 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 14 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 81 | 11 |
| Latanoprost | Latanoprost | 80 | 14 |
| Myrbetriq | Mirabegron | 80 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 80 | 12 |
| Sucralfate | Sucralfate | 80 | suppressed |
| Risperidone | Risperidone | 79 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 74 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 14 |
| Amoxicillin | Amoxicillin | 73 | 47 |
| Celecoxib | Celecoxib | 73 | suppressed |
| Baclofen | Baclofen | 72 | suppressed |
| Ezetimibe | Ezetimibe | 72 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 71 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 70 | 15 |
| Diazepam | Diazepam | 68 | 18 |
| Cefuroxime | Cefuroxime Axetil | 66 | 43 |
| Gemtesa | Vibegron | 65 | suppressed |
| Glipizide | Glipizide | 65 | suppressed |
| Bupropion Xl | Bupropion Hcl | 64 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 61 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 22 |
| Farxiga | Dapagliflozin Propanediol | 60 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | 15 |
| Mometasone Furoate | Mometasone Furoate | 58 | 22 |
| Nystatin | Nystatin | 53 | 24 |
| Divalproex Sodium Er | Divalproex Sodium | 52 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 52 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | suppressed |
| Lovastatin | Lovastatin | 52 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 52 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 51 | 51 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 50 | 12 |
| Estradiol | Estradiol | 50 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 38 |
| Ibuprofen | Ibuprofen | 48 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 48 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 48 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Gemfibrozil | Gemfibrozil | 40 | suppressed |
| Fluconazole | Fluconazole | 39 | 24 |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 33 |
| Ondansetron Odt | Ondansetron | 39 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 38 | 38 |
| Invega Sustenna | Paliperidone Palmitate | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 18 |
| Chlorthalidone | Chlorthalidone | 37 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 37 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Cephalexin | Cephalexin | 36 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 22 |
| Torsemide | Torsemide | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 15 |
| Prazosin Hcl | Prazosin Hcl | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 26 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 26 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 26 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Austedo | Deutetrabenazine | 23 | suppressed |
| Dayvigo | Lemborexant | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 23 | suppressed |
| Demeclocycline Hcl | Demeclocycline Hcl | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Latuda | Lurasidone Hcl | 22 | suppressed |
| Lumigan | Bimatoprost | 22 | suppressed |
| Tetrabenazine | Tetrabenazine | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Clozapine | Clozapine | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 18 |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 19 | 11 |
| Primidone | Primidone | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Travoprost | Travoprost | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Calcium Acetate | Calcium Acetate | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Loxapine | Loxapine Succinate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Nystop | Nystatin | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Invega | Paliperidone | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,121.31 · 64 records | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII, AIRSUPRA, Auvelity, CAPLYTA, COBENFY, Dexcom G6 Transmitter, FANAPT, GEMTESA, HETLIOZ, INGREZZA, JARDIANCE, KISUNLA, MOUNJARO, OTEZLA, PAXLOVID, REPATHA, REXULTI, UZEDY, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error